Treatment and prevention of glioblastoma
Inventors
SÁNCHEZ-PUELLES GONZÁLEZ-CARVAJAL, José María • BOTELLA CUBELLS, Luisa María • AGUADO SANCHEZ, Tania • CUESTA MARTÍNEZ, Ángel • ALBIÑANA DÍAZ, Virginia • VILLAR GOMEZ-DE LAS HERAS, Karina
Assignees
Alianza Espanola De Familias De Von Hippel-Lindau-Vhl • Consejo Superior de Investigaciones Científicas • Centro de Investigación Biomédica en Red
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12622884-B2
Publication Date
2026-05-12
Expiration Date
Abstract
The invention relates to the use of a selective β2 adrenergic receptor antagonist for treating glioma. In particular, the invention relates to the use of an alkanolamine derivative or a pharmaceutically acceptable acid-addition salt thereof for treating a glioblastoma in a patient.
Core Innovation
The invention relates to a method of treatment of glioma in a human patient by administering a therapeutically effective amount of a selective antagonist of the β2-adrenergic receptor. The selective β2-adrenergic receptor antagonist is described as the compound of formula I/II or a pharmaceutically acceptable acid addition salt thereof, including ICI 118,551 as an identified selective β2 antagonist.
The disclosed findings address a need for new therapies for glioma, including glioblastoma. In the disclosed experiments, ICI 118,551 decreases viability of U-87 glioblastoma cells and decreases gliosphere formation/expansion in a cancer stem cell context. The disclosed results also include modulation of molecular markers, with downregulation of stemness biomarkers and upregulation of neural differentiation markers.
The invention further reports that the treatment delays tumor progression in NSG mouse xenografts. Additional disclosed molecular findings involve miRNA-related changes, including miR-21, PDCD4, and PTEN. The disclosed strategy is characterized by selectively targeting β2-adrenergic receptor antagonism as a basis for therapeutic effectiveness in glioma.
Claims Coverage
The partial content provides one independent claim. It covers a method for treating glioma in a human patient by administering a selective β2-adrenergic receptor antagonist, with dependent claims refining patient and compound form characteristics.
Treating glioma with a selective β2-adrenergic receptor antagonist
A method of treatment of glioma in a human patient comprising administering a therapeutically effective amount of a selective antagonist of the β2-adrenergic receptor, wherein the selective antagonist is the compound of formula I/II or a pharmaceutically acceptable acid addition salt thereof.
The independent claim is centered on administering a therapeutically effective amount of a selective β2-adrenergic receptor antagonist (formula I/II or a pharmaceutically acceptable acid addition salt) to treat glioma in a human patient.
Stated Advantages
Decreases viability of U-87 glioblastoma cells.
Decreases gliosphere formation/expansion in a cancer stem cell context.
Downregulates stemness biomarkers and upregulates neural differentiation markers.
Delays tumor progression in NSG mouse xenografts.
Documented Applications
Method of treating glioma in a human patient.
Method of treating glioblastoma (glioblastoma multiforme) as a glioma subtype addressed in the described findings.
Interested in licensing this patent?